Recordati SpA
REC
Company Profile
Business description
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
Contact
Via Matteo Civitali 1
MIlan20148
ITAT: +39 2487871
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
4,700
Stocks News & Analysis
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
stocks
This US AI champion’s stock is too cheap to ignore
Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.
stocks
Why SpaceX is coming to your Super Fund
Most Australians will end up owning SpaceX — whether they like it or not.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,047.30 | 25.90 | -0.29% |
| CAC 40 | 8,421.14 | 46.84 | -0.55% |
| DAX 40 | 24,985.82 | 40.98 | -0.16% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,363.27 | 36.43 | -0.35% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 71,250.06 | 196.57 | 0.28% |
| NZX 50 Index | 13,495.63 | 132.32 | 0.99% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,828.70 | 27.90 | -0.32% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |